Dimenydrinate vs Ondansetron for PONV (DONV)

• Status: Recruiting
• Trial end date: 2022-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Thessaly
• Treatments: Dimenhydrinate; Ondansetron

Criteria

Inclusion Criteria:

• Age 18-75 years old

• ASA PS I-III

• Undergoing laparoscopic general surgery operations or laparoscopic gynecological operations

Exclusion Criteria:

• Refused to participate

• Age other than 18-75 years old

• Pregnant patients

• Non-elective operations

• Patients that are not able to receive p.os agents

• Medical history of Brugada Sdr or Brugada-like/related ECG abnormalities

• Long-Qt Sdr or concurrent use of medications that may cause long-QT ECG abnormalities

• Medical or family history of psychosis

• Allergy in dimenydrinate or in dimenydrinate drug versions

• Perioperative use of dexamethasone